Display options
Cite
North WG, Liu F, Tian R, et al. NMDA receptors are expressed in human ovarian cancer tissues and human ovarian cancer cell lines. Clin Pharmacol. 2015;7:111-7doi: 10.2147/CPAA.S90367.
North, W. G., Liu, F., Tian, R., Abbasi, H., & Akerman, B. (2015). NMDA receptors are expressed in human ovarian cancer tissues and human ovarian cancer cell lines. Clinical pharmacology : advances and applications, 7111-7. https://doi.org/10.2147/CPAA.S90367
North, William G, et al. "NMDA receptors are expressed in human ovarian cancer tissues and human ovarian cancer cell lines." Clinical pharmacology : advances and applications vol. 7 (2015): 111-7. doi: https://doi.org/10.2147/CPAA.S90367
North WG, Liu F, Tian R, Abbasi H, Akerman B. NMDA receptors are expressed in human ovarian cancer tissues and human ovarian cancer cell lines. Clin Pharmacol. 2015 Oct 23;7:111-7. doi: 10.2147/CPAA.S90367. eCollection 2015. PMID: 26566373; PMCID: PMC4627399.
Copy Download .nbib Format: NLM
Share it on

Clin Pharmacol. 2015 Oct 23;7:111-7. doi: 10.2147/CPAA.S90367. eCollection 2015.

NMDA receptors are expressed in human ovarian cancer tissues and human ovarian cancer cell lines.

Clinical pharmacology : advances and applications

William G North, Fuli Liu, Ruiyang Tian, Hamza Abbasi, Bonnie Akerman

Affiliations

  1. Department of Physiology and Neurobiology, Geisel School of Medicine at Dartmouth College, Lebanon, NH, USA.

PMID: 26566373 PMCID: PMC4627399 DOI: 10.2147/CPAA.S90367

Abstract

We have earlier demonstrated that breast cancer and small-cell lung cancer express functional NMDA receptors that can be targeted to promote cancer cell death. Human ovarian cancer tissues and human ovarian cancer cell lines (SKOV3, A2008, and A2780) have now been shown to also express NMDA-receptor subunit 1 (GluN1) and subunit 2B (GluN2B). Seventeen ovarian cancers in two arrays were screened by immunohistochemistry using polyclonal antibodies that recognize an extracellular moiety on GluN1 and on GluN2B. These specimens comprised malignant tissue with pathology diagnoses of serous papillary cystadenocarcinoma, endometrioid adenocarcinoma, and clear-cell carcinoma. Additionally, archival tissues defined as ovarian adenocarcinoma from ten patients treated at this institute were also evaluated. All of the cancerous tissues demonstrated positive staining patterns with the NMDA-receptor antibodies, while no staining was found for tumor-adjacent normal tissues or sections of normal ovarian tissue. Human ovarian adenocarcinoma cell lines (A2008, A2780, SKOV3) were demonstrated to express GluN1 by Western blotting, but displayed different levels of expression. Through immunocytochemistry utilizing GluN1 antibodies and imaging using a confocal microscope, we were able to demonstrate that GluN1 protein is expressed on the surface of these cells. In addition to these findings, GluN2B protein was demonstrated to be expressed using polyclonal antibodies against this protein. Treatment of all ovarian cell lines with antibodies against GluN1 was found to result in decreased cell viability (P<0.001), with decreases to 10%-25% that of untreated cells. Treatment of control HEK293 cells with various dilutions of GluN1 antibodies had no effect on cell viability. The GluN1 antagonist MK-801 (dizocilpine maleate) and the GluN2B antagonist ifenprodil, like antibodies, dramatically decreased the viability of A2780 ovarian tumor cells (P<0.01). Treatment of A2780 tumor xenografts with ifenprodil (2.5 mg/kg body weight/day) significantly reduced tumor growth in nu/nu mice. Our findings suggest that both GluN1 and GluN2B proteins as membrane components could be readily available targets for the treatment of most ovarian cancers.

Keywords: NMDA receptors; antibodies; inhibitors; ovarian cancer; potential therapy

References

  1. J Biol Chem. 1993 Feb 5;268(4):2836-43 - PubMed
  2. Rinsho Shinkeigaku. 2012;52(11):982-4 - PubMed
  3. J Pharmacol Exp Ther. 1992 Feb;260(2):925-32 - PubMed
  4. Acta Neuropathol. 2009 Dec;118(6):737-43 - PubMed
  5. Lancet Neurol. 2008 Dec;7(12):1091-8 - PubMed
  6. Intern Med. 2010;49(19):2167-73 - PubMed
  7. Nature. 1991 Nov 7;354(6348):31-7 - PubMed
  8. J Neural Transm (Vienna). 2011 Aug;118(8):1255-9 - PubMed
  9. J Biol Chem. 1996 Apr 19;271(16):9603-11 - PubMed
  10. Eur J Pharmacol. 1996 Feb 29;298(1):51-5 - PubMed
  11. Science. 2000 Feb 25;287(5457):1453-60 - PubMed
  12. Mol Pharmacol. 1993 Oct;44(4):851-9 - PubMed
  13. Clin Pharmacol. 2010;2:31-40 - PubMed
  14. Proc Natl Acad Sci U S A. 1995 Aug 1;92(16):7162-6 - PubMed
  15. J Biochem Toxicol. 1996;11(5):217-26 - PubMed
  16. Breast Cancer Res Treat. 2010 Jul;122(2):307-14 - PubMed
  17. Anesth Analg. 2009 Mar;108(3):1015-20 - PubMed
  18. Trends Pharmacol Sci. 2001 Dec;22(12):636-42 - PubMed
  19. Mol Pharmacol. 1989 Nov;36(5):758-65 - PubMed
  20. Eur J Pharmacol. 1992 Aug 3;226(4):373-6 - PubMed
  21. Brain Res. 2011 May 10;1389:152-60 - PubMed
  22. Eur J Pharmacol. 1989 Aug 3;166(3):591-2 - PubMed

Publication Types

Grant support